Quetiapine for Delirium Prophylaxis in High-risk Critically Ill Patients

Objective: To evaluate the efficacy of scheduled quetiapine for delirium prophylaxis in critically ill, trauma/surgical patients identified as high-risk for delirium utilizing a validated prediction model.

Design: Prospective, open-label, single-center study. Setting: Trauma/surgical intensive care unit at an academic medical center. Patients: Eighty two adult trauma/surgical patients who were admitted to the intensive care unit and were at high-risk for the development of delirium (PRE-DELIRIC Score ≥50%, past medical history of dementia, past medical history of alcohol misuse, or past medical history of drug abuse).

Interventions: Patients were randomized by unit location to receive pharmacologic prophylaxis for delirium (quetiapine 12.5 mg every 12 hours) or no pharmacologic prophylaxis for delirium within forty-eight hours of admission to the intensive care unit.

Measurements: The primary end point was the incidence of delirium during admission to the intensive care unit (ICU). Secondary end points included time to onset of delirium, ICU and hospital lengths of stay, ICU and hospital mortality, duration of mechanical ventilation, and adverse events. Delirium was assessed using the confusion assessment method for the intensive care unit.

Inclusion criteria

• Trauma/surgical patients admitted to the trauma/surgical ICU

Exclusion criteria

• sustained RASS of -4/-5 during the complete ICU admission
• presence of a condition preventing delirium assessment
• anticipated or known ICU length of stay of less than 48 hours
• taking antipsychotics prior to admission
• history of schizophrenia, epilepsy, parkinsonism, or levodopa treatment
• primary neurologic event/injury with GCS ≤ 9 during the first 48 hours of ICU
• current treatment with a continuous infusion neuromuscular blocking agent
• pregnancy
• screened positive for delirium upon admission to the ICU.